Clinical Trial

Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia

Study acronym: SHORTEN2
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-01-14; most recent amendment 2026-01-20.
Status change: Recruiting → Active, Not Recruiting 2026-01-20
Status change: Not Yet Recruiting → Recruiting 2022-05-20
Trial Details
NCT Number NCT05210439
Lead Sponsor Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborators: Spanish Clinical Research Network - SCReN, Centers for International Business Education and Research
Conditions Bloodstream Infection
Enrollment 306 participants
Start Date 2022-04-28
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-22